Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Furoic acid + loperamide** is a combination medication consisting of furoic acid (likely intended as "furazolidone", a synthetic nitrofuran antibacterial agent) and loperamide, a peripherally-acting mu-opioid receptor agonist used as an antidiarrheal. Loperamide acts by slowing intestinal motility and increasing fluid absorption, making stools more solid and less frequent. Furazolidone (if "furoic acid" is interpreted as such) acts by damaging bacterial DNA, thus killing diarrhoea-causing microorganisms. The combination is indicated primarily for the treatment of **infectious diarrhoea**, leveraging both antibacterial and antimotility effects for symptomatic relief and eradication of the underlying infection[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on furoic acid + loperamide.